Felix Feng

Felix Feng

Felix Y. Feng, M.D.

Vice Chair for Faculty Development

and Translational Research,

Department of Radiation Oncology

Associate Professor of Radiation Oncology,
Urology, and Medicine

University of California, San Francisco
Helen Diller Family Cancer Research Building
Box 3110,1450 Third Street, Room 383
San Francisco, CA 94158
Phone: 415 502-7222
Fax: 415 476-7370

Research Website

 

Make A Gift Button

 

Professional Focus

Dr. Felix Feng is a radiation oncology leader in translational research. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive prostate cancer, by identifying determinants of treatment resistance and developing strategies to overcome this resistance.

To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.

Dr. Feng serves on the National Cancer Institute Genitourinary Cancer Steering Committee, which oversees and evaluates clinical trials proposed by all national clinical trials cooperative groups. He also serves as Chair of the Biology Scientific Track for the American Society of Radiation Oncology, and as Chair of the Genitourinary Translational Research Program for the RTOG/NRG national cooperative group.

 

Education

1994-1998 Stanford University BS Distinction and Honors in Biological Sciences
1998-2002 Washington University School of Medicine MD  
2002-2003 Saint Joseph Mercy Hospital, Ypsilanti, Michigan Internship Internal Medicine
2003-2005 University of Michigan Medical Center, Ann Arbor, Department of Radiology Resident Radiology
2005-2006 University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology Postdoctoral Research Fellow Radiation Biology
2006-2010 University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology Resident Radiation Oncology
2009-2010 University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology Chief Resident Radiation Oncology
       

 

Professional Experience

  PRINCIPAL POSITIONS HELD    
2013-2016 University of Michigan, Ann Arbor Director, Division of Translational Genomics Radiation Oncology
2010-2016 University of Michigan, Ann Arbor Assistant Professor Radiation Oncology
2016-present University of California, San Francisco Vice Chair for Faculty Development and Translational Research Radiation Oncology
2016-present University of California, San Francisco Associate Professor of Radiation Oncology, Urology, and Medicine Radiation Oncology and Urology
  OTHER POSITIONS HELD CONCURRENTLY    
2010-2016 The University of Michigan Comprehensive Cancer Center Primary: Prostate Cancer Program Secondary: Radiation Sciences Core Member Radiation Oncology
2010-2016 Ann Arbor Veteran's Health System, Ann Arbor, Michigan Assistant Professor Radiation Oncology
2011-2011 Ann Arbor Veteran's Health System, Ann Arbor, Michigan Acting Chief Radiation Oncology
2011-2016 University of Michigan Chair Genitourinary Translational Research Program for the NRG/RTOG Cooperative Trials Group
2011-2016 Allegiance Health System, Jackson, Michigan Active Staff Radiation Oncology
2011-2016 Ingham Regional Medical Center, Lansing, Michigan Active Staff Radiation Oncology
2011-2016 Providence Hospital, Southfield, Michigan Active Staff Radiation Oncology
2015-2016 University of Michigan, Ann Arbor Associate Chair for Laboratory Research Radiation Oncology
2010-present NRG/RTOG Cooperative Group Leader Genitourinary Cancer Translational Research Program

 

Awards & Honors

1994 President's Scholar for Academic Achievement (for scholastic achievement at Stanford University)
1995 President's Award for Academic Excellence (for scholastic achievement at Stanford University)
1997 Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering (national collegiate award/grant for outstanding basic science research)
1998 Dr. Philip Majerus Distinguished Alumni Scholarship 1998-2002 (full-tuition, four-year merit scholarship at the Washington University School of Medicine, awarded to three students per class)
1999 Washington University Research Award (best summer research project among med students)
2000 American College of Physicians Award for Excellence in Physical Diagnosis
2000 Best Presentation, Midwest Association of Plastic Surgeons Conference
2000 McLaughlin Award, National Student Research Forum (for best presentation in immunology)
2002 Dr. Richard S. Brookings Medical School Prize (awarded for the highest achievement in research among the graduating medical school class)
2002 Missouri State Medical Association Award (for scholastic achievement in medical studies)
2006 Merit award, Translational Research Symposium, ASTRO
2006 First place presentation, Michigan Society of Therapeutic Radiation Oncology (MSTRO) Resident Research Competition
2008 ASTRO Resident Clinical Research Award (for the best abstract submitted by a resident physician to the annual meeting)
2009 Travel grant, Radiation Therapy Oncology Group annual meeting
2009 Resident Scholarship for American Brachytherapy Society/Seattle Prostate Brachytherapy course
2010 Radiological Society of North America Roentgen Resident/Fellow Research Award
2012 American Society of Radiation Oncology Basic Science Award (for the best basic science abstract submitted to the annual meeting of this group)
2014 Teacher of the Year, Radiobiology, Department of Radiation Oncology, University of Michigan
2016 American Society of Radiation Oncology Clinical Science Award (for the best clinical science abstract submitted to the annual meeting of this group)

 

Recent Significant Publications :

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. JAMA Oncol. 2016 Jan 7:1-10. PMID: 26746117

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. Cancer Cell. 2015 Jul 13;28(1):97-113. PMID: 26175416

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Int J Radiat Oncol Biol Phys. 2015;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. PubMed PMID: 26530751.

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB,Feng FY. Eur Urol. 2015 Oct;68(4):555-67. PMID: 25964175

The landscape of long noncoding RNAs in the human transcriptome. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. Nature Genetics. 2015 Mar;47(3):199-208.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Nature. 2014;510(7504):278-82.

A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. Clin Cancer Research. 2014 Dec 15;20(24):6379-88.

RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. Lancet Oncol. 2014 Dec;15(13):1469-80. PMID:25456366

The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY. Neoplasia. 2014 Nov 20;16(11):900-8.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. Cancer Res. 2014 Mar 15;74(6):1651-60. PMID: 24473064